Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Cytodyn Inc (Cytodyn) is a biotechnology company focused on in the development of therapeutic products. The company's main activities include research and development in the fields of oncology, inflammation, and HIV treatment. Its developing product pipeline for various conditions such as colorectal cancer, triple-negative breast cancer, glioblastoma, prostate cancer, chronic inflammation, and HIV. Cytodyn collaborates with pharmaceutical and biotechnology companies to advance its product development. Cytodyn is headquartered in Vancouver, Washington, the US.
Headquarters
United States of America
Address
Suite 660, 1111 Main Street, Vancouver, Washington, 98660
Website
www.cytodyn.com
Telephone
1 360 9808524
No of Employees
13
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
CYDY (OTC)
EPS
XYZ
Net Income (2024)
XYZ
107.5%
(2024 vs 2023)
Market Cap*
$327.1M
Net Profit Margin (2021)
XYZ
0.0%
(2024 vs 2023)
* As of and is in US$
Cytodyn Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| Oncology: |
| Colorectal Cancer |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Regulatory Approval | In November, the company received FDA clearance for a Phase II trial evaluating leronlimab in patients with relapsed/refractory microsatellite stable colorectal cancer. |
| 2024 | Others | In August, the company submitted a study protocol to the U.S. FDA to align on the rationale and proposed dosing for a Phase II study investigating the safety and activity of leronlimab combined with trifluridine/tipiracil (TAS-102) and bevacizumab in participants with CCR5+, microsatellite stable, relapsed or refractory metastatic colorectal cancer. |
| 2022 | Financing Agreements | In April, the company announced to raise US$1.89 million in equity financing. |
Competitor Comparison
| Key Parameters | Cytodyn Inc | Merck & Co Inc | Beigene USA Inc | Celgene Corp | Jazz Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Vancouver | Rahway | Cambridge | Princeton | Palo Alto |
| State/Province | Washington | New Jersey | Massachusetts | New Jersey | California |
| No. of Employees | 13 | 75,000 | - | - | - |
| Entity Type | Public | Public | Private | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Tanya Durkee Urbach | Chairman | Executive Board | 2022 | 58 |
| Jacob P. Lalezari | Chief Executive Officer | Senior Management | 2024 | 66 |
| Robert E. Hoffman | Chief Financial Officer | Senior Management | 2025 | 59 |
| Bernie Cunningham, PhD | Vice President - Operations | Senior Management | - | - |
| Cyrus Arman, PhD | Senior Vice President - Business Operations | Senior Management | 2022 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer